Valuation: Galderma Group AG

Market Cap 48.45B 42.35B 39.17B 35.94B 68.02B 4,669B 69.21B 467B 183B 2,280B 182B 178B 7,872B P/E 2026 *
55.7x
P/E 2027 * 37.2x
Enterprise Value 49.98B 43.68B 40.4B 37.07B 70.16B 4,816B 71.38B 482B 189B 2,352B 188B 184B 8,119B EV / Sales 2026 *
7.94x
EV / Sales 2027 * 6.53x
Free-Float
77.58%
Yield 2026 *
0.27%
Yield 2027 * 0.41%
1 day+1.44%
1 week-2.58%
Current month-7.61%
1 month-0.79%
3 months+11.96%
6 months+6.79%
Current year+4.81%
1 week 166.25
Extreme 166.25
175.65
1 month 166.15
Extreme 166.15
188.25
Current year 136.3
Extreme 136.3
188.25
1 year 122.7
Extreme 122.7
188.25
3 years 60
Extreme 60
188.25
5 years 60
Extreme 60
188.25
10 years 60
Extreme 60
188.25
Date Insider Type Main position Quantity % Market Cap.
29/4/26 Buy 15,000 0.0063%
28/4/26 Sell 25,000 0.0105%
28/4/26 Buy 20,000 0.0084%
Change 5-day change 1-year change 3-year change Capi.($)
+1.98%-2.58%+36.14% - 48.45B
+0.73%+0.45%+4.77%-7.88% 231B
+1.95%+1.95%+123.17% - 9.69B
+1.32%+8.50%+22.68%-52.17% 7.36B
+2.98%+0.08%-10.76%+17.69% 5.02B
+0.47%-1.28%-31.08%-36.97% 4.37B
+1.89%+3.97%-7.65%-8.52% 3.85B
+0.37%+3.97%-25.91%-46.71% 3.48B
+1.14%+3.84%-18.24%-47.11% 2.64B
-6.10%-4.96%-1.42% - 2.04B
Average +0.62%+1.45%+9.17%-25.95% 31.8B
Weighted average by Cap. +0.89%-0.72%+12.11%-10.07%

Financials

2026 *2027 *
Net sales 6.31B 5.52B 5.1B 4.68B 8.86B 608B 9.01B 60.85B 23.9B 297B 23.7B 23.18B 1,025B 7.38B 6.45B 5.97B 5.48B 10.36B 711B 10.54B 71.16B 27.96B 347B 27.72B 27.11B 1,199B
Net income 869M 760M 702M 645M 1.22B 83.73B 1.24B 8.38B 3.29B 40.89B 3.26B 3.19B 141B 1.29B 1.12B 1.04B 954M 1.8B 124B 1.84B 12.39B 4.87B 60.5B 4.83B 4.72B 209B
Net Debt 1.52B 1.33B 1.23B 1.13B 2.14B 147B 2.18B 14.68B 5.77B 71.67B 5.72B 5.59B 247B 347M 303M 281M 257M 487M 33.44B 496M 3.35B 1.31B 16.33B 1.3B 1.27B 56.37B
Logo Galderma Group AG
Galderma Group AG is a Switzerland based holding Company, specializing in dermatological treatments and skin care products. The Company, throw its subsidiaries, operates a portfolio of carious self-care brands focusing primarily on dermatological solutions, through its subsidiaries. production within the portfolio include neuromodulators, fillers. and biostimulators. these products are designed to relax winkles via injection, fill wrinkles in a specific location via injection and stimulate the body's cells to function optimally. The production process, for the various products primarily takes place in house, form research and development to manufacturing. In addition, including education, scientific engagements, and other services are offered.
Employees
7,676
Date Price Change Volume
16/07/26 CHF 169.90 +1.98% 430,444
15/07/26 CHF 166.60 -1.27% 310,091
14/07/26 CHF 168.75 -1.11% 295,317
13/07/26 CHF 170.65 -1.27% 389,444
10/07/26 CHF 172.85 -0.89% 389,388
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
206.56USD
Average target price
232.97USD
Spread / Average Target
+12.79%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GALD Stock